REGENXBIO Inc. (RGNX)
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RGNX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $473.44M
- EPS (TTM)
- -$3.20
- Dividend yield
- None
- 52-week range
- 5.46 – 16.19
- Day range
- 6.86 – 7.30
- Volume / Avg
- 1.05M / 1.39M
- Beta
- —
- Shares outstanding
- 66.12M
52-week range
RGNX stock today
REGENXBIO (RGNX) closed at $7.16 on Nov 20, down 0.28% (-$0.02), versus the S&P 500's 3.70% decline. Shares are 55.8% below their 52-week high of $16.19, set on Jan 22, 2026 and 31.3% above the 52-week low of $5.46, near the bottom of the past year's range. RGNX is down 50.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 39.3%.
REGENXBIO has posted a net loss over the last twelve months (EPS of -$3.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About REGENXBIO
Company profileREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Curran M. Simpson M.S.
- Headquarters
- Rockville, MD
- Employees
- 371
- IPO year
- 2015
- Website
- regenxbio.com
Financial highlights
Full financialsIn fiscal 2025, REGENXBIO generated $170.4 million in revenue, up 104.5% from fiscal 2024. REGENXBIO reported a net loss of $193.9 million, compared with a loss of $227.1 million a year earlier. Operating margin was -94.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $170.44M | $83.33M | $90.24M | $112.72M | $470.35M |
| Growth | +104.54% | -7.66% | -19.94% | -76.03% | +204.30% |
| Net income | $-193.88M | $-227.10M | $-263.49M | $-280.32M | $127.84M |
| EPS (diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$21.40+198.88%
- Strong buy 3
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.62 vs $-1.35
- Surprise
- +54.07%
RGNX news
All RGNX news- Regenxbio outlines RGX-202 full BLA filing in Q1 2027 with cash runway late into Q4 2027Seeking Alpha
- Regenxbio Inc Q3 Loss DropsNasdaq
- REGENXBIO Reports Third Quarter 2026 Financial Results and Operational HighlightsPR Newswire
- 4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesNasdaqTGTX, RGNX, IMNM, PMN
- REGENXBIO to Participate in Stifel 2026 Healthcare ConferencePR Newswire
- REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsPR Newswire
- REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20PR Newswire
REGENXBIO peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs RGNX |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs RGNX |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs RGNX |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs RGNX |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs RGNX |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs RGNX |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs RGNX |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs RGNX |
Indexes, lists and sector
REGENXBIO stock FAQ
What is REGENXBIO's stock price today?
RGNX last traded at $7.16 as of Nov 20, 4:00 PM EST, down 0.28% on the day. Prices are delayed at least 15 minutes.
Who is REGENXBIO's CEO?
Mr. Curran M. Simpson M.S. is the chief executive officer of REGENXBIO Inc., which has about 371 employees.
What is the RGNX 52-week high?
The 52-week high for RGNX is $16.19 and the 52-week low is $5.46. The stock is currently 55.8% below its high.